Johnson & Johnson Innovation

Johnson and Johnson Innovation is the umbrella for J and J’s corporate venture, business development, and incubator activities, including JJDC (Johnson and Johnson Development Corporation) which deploys equity capital into life sciences, medical devices, consumer health, and selectively digital health companies. JJDC writes checks generally in the $5M to $25M range at Series A through C, often as a strategic minority alongside financial leads, with the explicit goal of building partnership and acquisition pipeline for J and J’s operating divisions. Healthcare exposure is total and spans the breadth of J and J’s businesses including pharmaceuticals, medical devices, and consumer health. AI focus is meaningful in drug discovery, medical imaging, surgical robotics adjacent to Ethicon, and digital therapeutics. Founders best suited are Series A and B CEOs in therapeutics, devices, surgical AI, or digital health with a clear strategic angle to one of J and J’s operating divisions, who can manage the complexity of a large pharma corporate investor and want strategic value beyond capital. Founders who do not fit include digital health services-only businesses without a J and J angle, consumer wellness, and pre-product seed teams. Geographic preference is global with concentrations in the US, Europe, and selectively Asia. The entry path is warm introduction through a J and J operating division business development executive, a JJDC investor, a JLABS resident or alumnus, or a portfolio CEO. LinkedIn outreach with a clear strategic articulation is a reasonable secondary option. Expect long diligence cycles and structured partnership conversations alongside equity terms.